Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.57 |
| ▸ | CA2 | P00918 | 3/20 | 0.57 |
| ▸ | CA12 | O43570 | 2/20 | 0.57 |
| ▸ | CA7 | P43166 | 2/20 | 0.57 |
| ▸ | CA9 | Q16790 | 2/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | STS | P08842 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13019487 | 0.94 | CA1 (0.53) | CA1CA2CA12CA7CA9 | |
| SCHEMBL28993944 | 0.82 | CA1 (0.80) | CA1CA2CA12CA7CA9 | |
| SCHEMBL23600 | 0.82 | CA1 (0.80) | CA1CA2CA12CA7CA9 | |
| SCHEMBL11743710 | 0.79 | ACR (0.49) | CA1CA2MAPTALDH1A1MEN1 | |
| SCHEMBL28704033 | 0.79 | CA1 (0.76) | CA1CA2CA12CA7CA9 | |
| Ammonia Solution, Strong SCHEMBL28873355 | 0.79 | CA1 (0.76) | CA1CA2CA12CA7CA9 | |
| SCHEMBL28531063 | 0.79 | CA1 (0.76) | CA1CA2CA12CA7CA9 | |
| SCHEMBL28993277 | 0.79 | CA1 (0.76) | CA1CA2CA12CA7CA9 | |
| Water SCHEMBL22720573 | 0.79 | CA1 (0.76) | CA1CA2CA12CA7CA9 | |
| Methyl Alcohol SCHEMBL28561085 | 0.79 | CA1 (0.76) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011330-A1 | Imidazo[1,2- a]pyrazine and Imidazo[1,2- a]pyridine Based Tyrosyl-DNA Phosphodiesterase I (TDP1) Inhibitors | LEIDOS BIOMEDICAL RESEARCH INC. | 2025-01-09 | — | — | US | disclosed |
| EP-4284798-A1 | IMIDAZO[1,2-A]PYRAZINE AND IMIDAZO[1,2-A]PYRIDINE BASED TYROSYL-DNA PHOSPHODIESTERASE I (TDP1) INHIBITORS | The USA, as represented by The Secretary, Department of Health and Human Services (US) | 2023-12-06 | — | — | EP | disclosed |
| EP-3562810-B1 | BENZHYDROXAMIC ACID DERIVATIVES AS SELECTIVE HDAC6 INHIBITORS | ITALFARMACO SPA (IT) | 2023-05-03 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2022164934-A1 | IMIDAZO[1,2-A]PYRAZINE AND IMIDAZO[1,2-A]PYRIDINE BASED TYROSYL-DNA PHOSPHODIESTERASE I (TDP1) INHIBITORS | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2022-08-04 | — | — | WO | disclosed |
| US-11351178-B2 | Selective HDAC6 inhibitors | ITALFARMACO SPA (IT) | 2022-06-07 | — | — | US | disclosed |
| US-20210128577-A1 | Selective HDAC6 Inhibitors | ITALFARMACO S.P.A. (IT) | 2021-05-06 | — | — | US | disclosed |
| US-10906886-B2 | Substituted 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazines as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-02 | — | — | US | disclosed |
| EP-3562810-A1 | SELECTIVE HDAC6 INHIBITORS | Italfarmaco SpA (IT) | 2019-11-06 | — | — | EP | disclosed |
| EP-2978751-B1 | TETRAHYDROISOQUINOLINES CONTAINING SUBSTITUTED AZOLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-12-05 | — | — | EP | disclosed |
| US-20110059934-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2011-03-10 | — | — | US | disclosed |
| WO-2011006143-A2 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2011-01-13 | — | — | WO | disclosed |
| US-7816540-B2 | Carboxyl- or hydroxyl-substituted benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20100204487-A1 | PROCESS FOR MAKING THIOPHENE CARBOXAMIDE DERIVATIVES | DAVIES IAN | 2010-08-12 | — | — | US | disclosed |
| US-20100003250-A1 | (2-ARYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)MORPHOLINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2010-01-07 | — | — | US | disclosed |
| WO-2010002954-A1 | (2-ARYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)MORPHOLINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2010-01-07 | — | — | WO | disclosed |
| US-20090247596-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK CANADA INC. (CA) | 2009-10-01 | — | — | US | disclosed |
| US-20090163552-A1 | CARBOXYL- OR HYDROXYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2009-06-25 | — | — | US | disclosed |
| US-20090023918-A1 | PROCESS FOR PREPARING 3-ACYLAMINOBENZOFURAN-2-CARBOXYLIC ACID DERIVATIVE | SEKI MASAHIKO | 2009-01-22 | — | — | US | disclosed |
| US-7439368-B2 | Process for producing 3-acylaminobenzofuran-2-carboxylic acid derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204487-A1 | PROCESS FOR MAKING THIOPHENE CARBOXAMIDE DERIVATIVES | PTGER4, P2RY4, PTGES2 | CA1 3046/4885CA2 1586/4885CA12 3658/4885 |
| US-20210128577-A1 | Selective HDAC6 Inhibitors | HDAC6, HDAC1, HDAC3 | CA1 908/4885CA2 1698/4885CA12 1408/4885 |
| US-20110059934-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF PARASITIC DISEASES | SQLE, SGMS2, FDPS | CA1 3546/4885CA2 1439/4885CA12 1639/4885 |
| US-10906886-B2 | Substituted 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazines as factor xia inhibitors | TFPI, F12, F11 | CA1 1725/4885CA2 1537/4885CA12 2826/4885 |
| US-20250011330-A1 | Imidazo[1,2- a]pyrazine and Imidazo[1,2- a]pyridine Based Tyrosyl-DNA Phosphodiesterase I (TDP1) Inhibitors | TDP1, TDP2, TOP1 | CA1 4281/4885CA2 3277/4885CA12 4802/4885 |
| US-20090247596-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | PTGER4, PTGER1, PTGER2 | CA1 4007/4885CA2 1544/4885CA12 3464/4885 |
| US-20100003250-A1 | (2-ARYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)MORPHOLINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, RICTOR, MAPKAP1 | CA1 4760/4885CA2 1747/4885CA12 4870/4885 |
| US-11351178-B2 | Selective HDAC6 inhibitors | HDAC6, HDAC1, HDAC3 | CA1 988/4885CA2 1673/4885CA12 1400/4885 |
| US-20090023918-A1 | PROCESS FOR PREPARING 3-ACYLAMINOBENZOFURAN-2-CARBOXYLIC ACID DERIVATIVE | F12, F3, F11 | CA1 808/4885CA2 486/4885CA12 701/4885 |
| US-20090163552-A1 | CARBOXYL- OR HYDROXYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | NR1H4, GPBAR1, SLC10A1 | CA1 2644/4885CA2 715/4885CA12 3001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.